Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 7/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26967719 | 0.90 | KDM4E (0.43) | DRD4HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL26967721 | 0.89 | DRD4 (0.40) | DRD4HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL26967647 | 0.82 | ALDH1A1 (0.62) | HTR1AHTR1DHTR1BALDH1A1LMNA | |
| SCHEMBL29908987 | 0.78 | ALDH1A1 (0.45) | HTR1AHTR1DHTR1BDRD2DRD3 | |
| SCHEMBL26967713 | 0.78 | ALDH1A1 (0.48) | HTR1AHTR1DHTR1BALDH1A1LMNA | |
| SCHEMBL23029670 | 0.77 | KLK7 (0.53) | — | |
| SCHEMBL29636731 | 0.77 | KLK7 (0.53) | — | |
| SCHEMBL26967705 | 0.76 | HTR6 (0.49) | DRD2DRD3ALDH1A1POLBMAPT | |
| SCHEMBL26967687 | 0.75 | HSD17B10 (0.55) | DRD2DRD3HTR6KDM4E | |
| SCHEMBL26967659 | 0.74 | DRD2 (0.45) | DRD2DRD3ALDH1A1MAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148722-A1 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4294811-A2 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022178338-A2 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148722-A1 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | TARDBP, FUS, HSPE1 | DRD4 3982/4885HTR1A 1701/4885HTR1D 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.